RxDoctor Payments Data

Patricia Jett, MD

Family Medicine · Annapolis, MDNPI 1609877018

Payments from drug & device makers

$8,870in general payments, 2019–2025

Across 404 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$1K
  • Novo Nordisk$856
  • AstraZeneca$648
  • Pfizer$598
  • Lilly USA, LLC$474
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$1,20014%
  • Food & beverage$7,67086%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,870 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$169,625
Medicare patients
371
Services billed
3,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$42,579
XareltoRivaroxaban15$23,247
EliquisApixaban25$22,779
Lisdexamfetamine Dimesylate18$5,155
PremarinEstrogens, Conjugated16$4,226
Rosuvastatin Calcium144$3,993
SynthroidLevothyroxine Sodium48$2,817
Losartan Potassium131$2,547
Atorvastatin Calcium181$2,333
Metoprolol Succinate131$2,267
Amlodipine Besylate308$2,149
Propranolol Hcl ErPropranolol Hcl18$2,063
Ezetimibe24$2,057
Pantoprazole Sodium75$1,737
Duloxetine Hcl37$1,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$856$42,57934 claims
PfizerEliquis, Premarin$598$27,00441 claims
Johnson & JohnsonXarelto$187$23,24715 claims
AbbVieSynthroid, Armour Thyroid$1,315$3,69559 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,194139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →